Legend Biotech (LEGN) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)

Legend Biotech (LEGN) Net Income towards Common Stockholders Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 18.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 92.37%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Legend Biotech 7.11 Bn 6.46 Bn 129.70 Mn 45.50%

Historic Data

Download Data
DateValue
Mar 31, 2026 45.50%
Dec 31, 2025 47.70%
Sep 30, 2025 69.31%
Jun 30, 2025 -582.66%
Mar 31, 2025 -68.78%
Dec 31, 2024 33.27%
Sep 30, 2024 -101.46%
Jun 30, 2024 90.86%
Mar 31, 2024 46.66%
Dec 31, 2023 34.83%
Sep 30, 2023 26.78%
Jun 30, 2023 -3.05%
Mar 31, 2023 -247.18%
Dec 31, 2022 -53.82%
Sep 30, 2022 31.90%
Jun 30, 2022 -211.97%
Mar 31, 2022 -35,570.18%
Dec 31, 2021 -52.76%
Sep 30, 2021 -87.47%
Jun 30, 2021 227.95%